A new prostate cancer therapeutic approach: Combination of androgen ablation with COX-2 inhibitor

International Journal of Cancer

Volumn 123, Issue 1, 2008, Pages 195-201

  Cai, Yi ^a   Lee, Yi Fen ^a   Li, Gonghui ^a,b   Liu, Su ^a   Bao, Bo Ying ^a   Huang, Jiaoti ^a   Hsu, Cheng Lung ^c   Chang, Chawnshang ^a,d  

^a George H Whipple Laboratory for Cancer Research   (United States)

^b ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^c Chung Gong University/Hospital ^*  (Taiwan)

^d UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

Combined androgen blockade; Cyclooxygenase 2; Prostate cancer

Indexed keywords

ANDROSTANOLONE; CYCLOOXYGENASE 2; HYDROXYFLUTAMIDE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE;

ANIMAL CELL; ARTICLE; BIOASSAY; CANCER CELL; CANCER HORMONE THERAPY; CELL GROWTH; DRUG ANTAGONISM; ENZYME RELEASE; ENZYME REPRESSION; GENE OVEREXPRESSION; GENETIC TRANSCRIPTION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MALE; MODULATION; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE CANCER; SIGNAL TRANSDUCTION; TREATMENT RESPONSE;

ANDROGEN ANTAGONISTS; ANDROGENS; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLOTTING, WESTERN; CELL PROLIFERATION; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; DISEASE PROGRESSION; FLUORESCENT ANTIBODY TECHNIQUE; FLUTAMIDE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; NF-KAPPA B; NITROBENZENES; POLYMERASE CHAIN REACTION; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SULFONAMIDES; TRANSFECTION; TUMOR CELLS, CULTURED; UP-REGULATION;

EID: 43949125509     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.23481     Document Type: Article

References (47)

1. Kallioniemi O, Visakorp T. Genetic basis and clonal evolution of human prostate cancer. Adv Cancer Res 1996;68:225-55.
2. Greenlee RT, Hill-Harmon MB, Murray T, Thun M. Cancer statistics, 2001. CA Cancer J Clin 2001;51:15-36.
3. Huggins C, Hodges C. Studies on prostatic cancer: the effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1941;1:293-7.
4. Labrie F, Dupont A, Belanger A, Lefebvre F, Cusan L, Monfette G, Laberge J, Emond J, Raynaud J, Husson J, Fazekas A. New hormonal treatment in cancer of the prostate: combined administration of an LHRH agonist and an antiandrogen. J Steroid Biochem 1983; 19:999-1007.
5. Turkes A, Griffiths K. Endocrine treatment of prostate cancer. Prog Med Chem 1989;26:299-321.
6. Logothetis C, Hossan E, Smith T. SMS 201-995 in the treatment of refractory prostatic carcinoma. Anticancer Res 1994;14:2731-4.
7. Meric JB, Rottey S, Olaussen K, Soria JC, Khayat D, Rixe O, Spano JP. Cyclooxygenase-2 as a target for anticancer drug development. Crit Rev Oncol Hematol 2006;59:51-64.
8. Smith T, Leipprandt J, DeWitt D. Purification and characterization of the human recombinant histidine-tagged prostaglandin endoperoxide H synthases-1 and -2. Archiv Biochem Biophys 2000;375:195-200.
9. Hla T, Bishop-Bailey D. Liu CH, Schaefers HJ, Trifan OC. Cyclooxygenase-1 and -2 isoenzymes. Int J Biochem Cell Biol 1999;31:551-7.
10. Hussain T, Gupta S, Mukhtar H. Cyclooxygenase-2 and prostate carcinogenesis. Cancer Lett 2003;191:125-35.
11. Tsujii M, Kawano S, Tsuji S, Sawaoka H, Hori M, DuBois RN. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 1998;93:705-16.
12. Tsujii M, Kawano S, DuBois RN. Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc Natl Acad Sci USA 1997;94:3336-40.
13. Tsujii M, DuBois RN. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell 1995;83:493-501.
14. Takahashi Y, Kawahara F, Noguchi M, Miwa K, Sato H, Seiki M, Inoue H, Tanabe T, Yoshimoto T. Activation of matrix metalloproteinase-2 in human breast cancer cells overexpressing cyclooxygenase-1 or -2. FEBS Lett 1999;460:145-8.
15. Pold M, Krysan K, Pold A, Dohadwala M, Heuze-Vourc'h N, Mao JT, Riedl KL, Sharma S, Dubinett SM. Cyclooxygenase-2 modulates the insulin-like growth factor axis in non-small-cell lung cancer. Cancer Res 2004;64:6549-55.
16. Shappell S, Manning S, Boeglin W, Guan Y, Roberts R, Davis L, Olson S, Jack G, Coffey C, Wheeler T, Breyer M. Alterations in lipoxygenase and cyclooxygenase-2 catalytic activity and mRNA expression in prostate carcinoma. Neoplasia 2001;3:287-303.
17. Gupta S, Srivastava M, Ahmad N, Bostwick DG, Mukhtar H. Overexpression of cyclooxygenase-2 in human prostate adenocarcinoma. Prostate 2000;42:73-8.
18. Zha S, Gage WR, Sauvageot J, Saria EA, Putzi MJ, Ewing CM, Faith DA, Nelson WG, De Marzo AM, Isaacs WB. Cyclooxygenase-2 is up-regulated in proliferative inflammatory atrophy of the prostate, but not in prostate carcinoma. Cancer Res 2001;61:8617-23.
19. Wang W, Bergh A, Damber JE. Cyclooxygenase-2 expression correlates with local chronic inflammation and tumor neovascularization in human prostate cancer. Clin Cancer Res 2005;11:3250-6.
20. Saukkonen K, Nieminen O, Van Rees B, Vilkki S, Harkonen M, Juhola M, Mecklin JP, Sipponen P, Ristimaki A. Expression of cyclooxygenase-2 in dysplasia of the stomach and in intestinal-type gastric adenocarcinoma. Clin Cancer Res 2001;7:1923-31.
21. Wang W, Bergh A, Damber JE. Chronic inflammation in benign prostate hyperplasia is associated with focal upregulation of cyclooxygenase-2, Bcl-2, and cell proliferation in the glandular epithelium. The Prostate 2004;61:60-72.
22. Lin HK, Altuwaijri S, Lin WJ, Kan PY, Collins LL, Chang C. Proteasome activity is required for androgen receptor transcriptional activity via regulation of androgen receptor nuclear translocation and interaction with coregulators in prostate cancer cells. J Biol Chem 2002;277:36570-6.
23. Fujita H, Koshida K, Keller ET, Takahashi Y, Yoshimito T, Namiki M, Mizokami A. Cyclooxygenase-2 promotes prostate cancer progression. Prostate 2002;53:232-40.
24. Bao BY, Hu YC, Ting HJ, Lee YF. Androgen signaling is required for the vitamin D-mediated growth inhibition in human prostate cancer cells. Oncogene 2004;23:3350-60.
25. Altuwaijri S, Lin HK, Chuang KH, Lin WJ, Yeh S, Hanchett LA, Rahman MM, Kang HY, Tsai MY, Zhang Y, Yang L, Chang C. Interruption of nuclear factor {kappa}B signaling by the androgen receptor facilitates 12-O- tetradecanoylphorbolacetate-induced apoptosis in androgen-sensitive prostate cancer LNCaP cells. Cancer Res 2003;63:7106-12.
26. Lim JW, Kim H, Kim KH. Nuclear factor-kappaB regulates cyclooxygenase-2 expression and cell proliferation in human gastric cancer cells. Lab Invest J Tech Methods Pathol 2001;81:349-60.
27. Mohler J, Gaston K, Moore D, Schell M, Cohen B, Weaver C, Petrusz P. Racial differences in prostate androgen levels in men with clinically localized prostate cancer. J Urol 2004171:2277-80.
28. Spencer AG, Woods JW, Arakawa T, Singer II, Smith WL. Subcellular localization of prostaglandin endoperoxide H synthases-1 and -2 by immunoelectron microscopy. J Biol Chem 1998;273:9886-93.
29. Iniguez M, Rodriguez A, Volpert O, Fresno M, Redondo J. Cyclooxygenase-2: a therapeutic target in angiogenesis. Trends Mol Med 2003;9:73-8.
30. Hull MA. Cyclooxygenase-2: how good is it as a target for cancer chemoprevention? Eur J Cancer 2005;41:1854-63.
31. Grossmann M, Wood M, Celis E. Expression, specificity and immunotherapy potential of prostate-associated genes in murine cell lines. World J Urol 2001;19:365-70.
32. Debes JD, Tindall DJ. The role of androgens and the androgen receptor in prostate cancer. Cancer Lett 2002;187:1-7.
33. Feldman BJ, Feldman D. The development of androgen-independent prostate cancer. Nat Rev Cancer 2001;1:34-45.
34. Heinlein CA, Chang C. Androgen receptor (AR) coregulators: an overview. Endocr Rev 2002;23:175-200.
35. Heinlein CA, Chang C. Androgen receptor in prostate cancer. Endocr Rev 2004;25:276-308.
36. Ngan E, Hashimoto Y, Ma Z, Tsai M, Tsai S. Overexpression of cdc25B, an androgen receptor coactivator, in prostate cancer. Oncogene 2003;22:734-9.
37. Yang L, Wang L, Lin HK, Kan PY, Xie S, Tsai MY, Wang PH, Chen YT, Chang C. Interleukin-6 differentially regulates androgen receptor transactivation via PI3K-Akt, STAT3, and MAPK, three distinct signal pathways in prostate cancer cells. Biochem Biophys Res Commun 2003;305:462-9.
38. Yeh S, Lin HK, Kang HY, Thin TH, Lin MF, Chang C. From HER2/Neu signal cascade to androgen receptor and its coactivators: a novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cells. Proc Natl Acad Sci USA 1999;96:5458-63.
39. Arnold JT, Isaacs JT. Mechanisms involved in the progression of androgen-independent prostate cancers: it is not only the cancer cell's fault. Endocr Relat Cancer 2002;9:61-73.
40. Liu AY, Corey E, Bladou F, Lange PH, Vessella RL. Prostatic cell lineage markers: emergence of Bcl2+ cells of human prostate cancer xenograft LuCaP 23 following castration. Int J Cancer 1996;65:85-9.
41. 4L Wang M-H, Yeh S, Su C-Y, Young C, Chang C. Natural products and environmental androgens/antiandrogens. Androgens and androgen receptor: mechanisms, functions, and clinical applications. Springer. 2002;7:197-211.
42. Lee YF, Lin WJ, Huang J, Messing EM, Chan FL, Wilding G, Chang C. Activation of mitogen-activated protein kinase pathway by the antiandrogen hydroxyflutamide in androgen receptor-negative prostate cancer cells. Cancer Res 2002;62:6039-44.
43. Kirschenbaum A, Liu X, Yao S, Levine A. The role of cyclooxygenase-2 in prostate cancer. Urology 2001;58:127-31.
44. Ulrich CM, Bigler J, Potter JD. Non-steroidal anti-inflammatory drugs for cancer prevention: promise, perils and pharmacogenetics. Nat Rev Cancer 2006;6:130-40.
45. Pruthi RS, Derksen JE, Moore D, Carson CC, Grigson G, Watkins C, Wallen E. Phase II trial of celecoxib in prostate-specific antigen recurrent prostate cancer after definitive radiation therapy or radical prostatectomy. Clin Cancer Res 2006;12:2172-7.
46. Weatherall M, Aldington S, Caldwell B, Beasley R. Inconsistencies in cardiovascular data from COX-2 inhibitor trials - is it a class effect? J R Soc Med 2006;99:275-6.
47. Salpeter SR, Gregor P, Ormiston TM, Whitlock R, Raina P, Thabane L, Topol EJ. Meta-analysis: cardiovascular events associated with nonsteroidal anti-inflammatory drugs. Am J Med 2006;119:552-9.